cult to determine because many patients with asymptomatic A R do not seek medical care until symptoms arise.
Two options currently exist for the treatment of AR. Medical management, consisting primarily of vasodilator therapy, reduces A R through arteriolar vasodilatation. Vasodilators have been shown to prevent the deterioration of left ventricular dysfunction in symptom-free persons and thus prevent or delay the need for an operation to replace the diseased aortic valve. Once symptoms or left ventricular dysfunction has occurred, aortic valve replacement is indicated. 2 Because of the risks associated with surgical procedures and the palliative nature of medical treatment options, an intermediate and minimally invasive treatment to correct A R would be beneficial. Previous work in this area has focused on the development of implantable valves to correct diseased native valves. 34 The device we have developed, known as an aortic valve obturator, would be placed intraluminally and secured above the native aortic valve to the aortic wall. The obturator is intended to enlarge the armamentarium of treatment options for A R and could become the longterm treatment of choice for selected patients. 3, Flow probe to measure flows through system. 4, Capacitance chamber 1 to aid in regulation of pressure. 5, Capacitance chamber 2 to aid in regulation of pressure. 6, Resistance element to create diastolic pressure. 7, Fluid reservoir of system. 8, Console of Ventricular-assist device to simulate normal heart function. 9, Computer and MacLab to record pressures and flows within system.
M e t h o d s
Aortic valves, At the time of cardiac transplantation, aortic valves including the anulus and a portion of the ascending aorta were dissected from discarded recipient hearts. The valves were then stored in normal saline solution with antibiotics and refrigerated until testing. Before testing, the valve leaflets were shortened to create Significant regurgitation.
Testing system. To simulate the characteristics of the normal arterial system, a mock circulatory !oop system was created. This system was based on previous models of pulse duplicator systems for the testing of prosthetic valves (Fig. 1) . To simulate physiologic pressure-flow characteristics, resistive and capacitance elements were integrally designed components of the system. The system was powered by the Abiomed BVS 5000 ventricular-assist device (Abiomed, Inc, Danvers, Mass.). This pulsatile pneumatic pump is driven by an electromechanical console and contains two polyurethane chambers in a polycarbonate housing. A three-leaflet polyurethane valve separates the gravity-filled atrial chamber from the air-actuated ventricular chamber. A second valve, located on the outlet ventricular chamber, was secured in the open position for the pUrposes of our experiment. The Abiomed console was driven by a foot pump for better regulation of the pulse rate and pressure in our system.
The housing chamber for the experimental human aortic valves is shown in Fig. 2 . This chamber, along with the two capacitance chambers, were made of acrylic polymer. The housing chamber consisted of inflow and outflow conduits through which pressure transducer catheters were situated. Aortic valves Contained within designed sleeves were placed in the center of this chamber. The sleeves allowed the valve anulus to undergo dynamic changes, simulating in vivo conditions. The obturators, designed to reduce AR, were introduced through the top of this chamber. These obturators could be positioned within or above the valve and were could be completely removed from the flow canal.
The capacitance system consisted of two chambers. The first chamber was air-filled, which allowed fluid from the circuit to be maintained at a designated level during system operation. The second chamber housed a l~-inch diameter Penrose drain, through which fluid from the system flowed. This was surrounded by an air-sealed compartment that was pressure regulated to adjust the elasticity of the system. A clamp was placed distal to the chambers to create resistance in the system, which directly correlated with the diastolic pressure component of our system. These elements were manipulated to simulate the characteristics of in vivo arterial circulation. The entire circuit was connected with 70 Durameter 1/2-inch tubing (Baxter Healthcare Corp., Bentley Div., Irvine, Calif.). Normal saline solution at room temperature was the principal fluid used in this investigation.
Pressure measurements on each side of the valve were recorded with pressure transducers (Millar Instruments, Inc., Houston, Texas). The pressure transducers were placed 2 cm from each side of the valve. Obturator design. Six solid plastic obturators were designed. Fig. 3 illustrates the shapes, with a description of each obturator.
Experimental procedure. The aortic valves were first sewn into the sleeves and then placed within the testing chamber. The system was primed, and the manually powered pump was started. The pulse rate was kept at approximately 80 beats/rain, and the pressures were adjusted to between 120 and 160 mm Hg systolic and between 70 and 90 mm Hg diastolic. Flow through the valve was approximately 3 L/rain. Recordings were obtained at baseline (control). The obturator was then positioned at the level of the valve and recordings were repeated. This procedure was repeated four times, so that four paired sets of data were obtained for each obturator with each valve tested. The study period for each valve was approximately 2 hours. During this time there was no significant deterioration in valve function, as ensured by using each valve as its own control before placement of the obturator. The regurgitant fractions for each valve remained constant throughout the study period. Analysis of each separate recording was conducted, with gradients and regurgitant fractions tabulated along with statistical analysis performed.
Statistical analysis. Data were analyzed with SAS software (Statistical Analysis System, Cary, N.C.) on the Columbia Presbyterian Department of Surgery computer system. A mixed model (random and fixed factors), twoway analysis of variance was used for the analysis of balanced, replicate-measure data. Device treatment was considered a fixed effect, and the four valves used were considered random effects. Ap value lower than 0.05 was considered significant.
Results
Four separate valves were tested with six different obturators. All obturators resulted in significant reductions in regurgitant fractions. Devices 5 and 6 ( Fig. 3) resulted in the most significant reductions in AR, 38% and 36%, respectively. Obturator 3 reduced regurgitation by only 15%, which was still a statistically significant reduction (p < 0.0001).
No device created clinically significant aortic gradients. Device 3 resulted in the largest average gradient (7 + 9 mm Hg). A summary of regurgitant fractions and gradients is shown in Tables I and II.  Table III details 
Values are -+ standard deviation. *Design numbers correspond to Fig. 3 .
Discussion
Age, degree of left ventricular dysfunction, and symptoms guide physicians in determining the optimal treatment for patients with AR. When operation is delayed until left ventricular dysfunction occurs, outcomes vary; depressed preoperative ejection fraction and elevated left ventricular end-diastolic pressure are predictors of mortality. 6-8 Alternatively, aortic valve replacement in symptom-free patients with normal left ventricular function exposes them to the risks related to operation, anticoagulation, and prosthetic valves.
The natural history of chronic AR is excellent in symptom-free patients with normal left ventricular function who are treated with conservative, nonoperative management. Bonow and colleagues 9 followed up 77 patients for 7 years and found that 75% remained free of symptoms and had normal left ventricular function. Surveillance guidelines for these patients are therefore extremely important. Although the development of symptoms is readily apparent, deteriorating left ventricular function is not. Compensation of the left ventricle by hypertrophy and dilation requires close observation because survival is directly correlated with left ventricular function. 6q°
Optimal management for individual patients is variable, with vasodilator therapy and operation the opposite ends of the spectrum. Hydralazine, nifedipine, and enalapril have all shown beneficial effects in the treatment of patients with AR who are free of symptoms and have normal left ventricular function. 11-~3 Medical management is effective in prolonging the time to aortic valve replacement, although ventricular function continues to deteriorate at a slow rate.
At the other end of the spectrum is an operation to replace the diseased aortic valve. Mortality rates as low as 1.5% have been reported for elective, isolated aortic valve operations, s Mortality rates increase significantly with additional risk factors such as urgency, age, left ventricular end-diastolic pressure, ejection fraction, cardiac index, functional class, bypass time, and extent of coronary disease.6, a, 14-16 AR has itself been demonstrated to be an independent risk factors for operative mortality. 14 Along with the surgical risk factors, the prosthetic valve poses risks of stroke, infection, and anticoagulation. In addition, aortic valve reoperation increases the risk of mortality. The concept of treating AR without replacement of the native aortic valve originated with a valve prosthesis implanted in the descending aorta. 17 Since that time, surgical correction of valvular disease has focused on replacement of the diseased valve with either mechanical or biologic valves in the anatomic position. Alternative treatment of AR has focused mainly on transluminal valves positioned above the native valve. 3-s ' 18, 19 A less invasive treatment than aortic valve replacement would allow physicians to be more aggressive in addressing regurgitant aortic valves. Two experimental approaches currently being investigated are transluminal valve replacement and an external root device to decrease annular dilation.5, 18-20 Both are still in the early animal testing phases, with no reported patient trials.
Percutaneous placement of an obturator through the femoral artery is one alternative that could potentially decrease AR substantially through a solely transluminal approach. Several groups of patients would appear to benefit immediately from this type of device. Potential candidates are patients with acute regurgitation, in whom risks of operation may exceed 40%, elderly persons with poor ejection fractions, and other high risk groups in whom the risk of operation may outweigh the benefits. Depending on device efficacy, even patients at lower
